Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Non-cash Items (2020 - 2023)

Historic Non-cash Items for Mirum Pharmaceuticals (MIRM) over the last 4 years, with Q4 2023 value amounting to $131.8 million.

  • Mirum Pharmaceuticals' Non-cash Items rose 15517.48% to $131.8 million in Q4 2023 from the same period last year, while for Dec 2023 it was $131.8 million, marking a year-over-year increase of 15517.48%. This contributed to the annual value of $131.8 million for FY2023, which is 15517.48% up from last year.
  • As of Q4 2023, Mirum Pharmaceuticals' Non-cash Items stood at $131.8 million, which was up 15517.48% from $152.6 million recorded in Q3 2023.
  • In the past 5 years, Mirum Pharmaceuticals' Non-cash Items ranged from a high of $152.6 million in Q3 2023 and a low of $32.6 million during Q4 2021
  • For the 4-year period, Mirum Pharmaceuticals' Non-cash Items averaged around $66.8 million, with its median value being $51.8 million (2021).
  • Its Non-cash Items has fluctuated over the past 5 years, first plummeted by 1967.46% in 2021, then soared by 15517.48% in 2023.
  • Mirum Pharmaceuticals' Non-cash Items (Quarter) stood at $40.6 million in 2020, then decreased by 19.67% to $32.6 million in 2021, then surged by 58.24% to $51.6 million in 2022, then soared by 155.17% to $131.8 million in 2023.
  • Its Non-cash Items was $131.8 million in Q4 2023, compared to $152.6 million in Q3 2023 and $102.2 million in Q2 2023.